INTRODUCTION {#s1}
============

MicroRNA is a group of 19--22 nucleotide, small, single-stranded and conserved non-coding RNA that acts as a regulator of gene expression at both the post-transcriptional and the translational levels through acting on the 3'-untranslated region (UTR) of messenger RNA (mRNA) \[[@R1]\]. MicroRNAs involve in various biological processes associated with the tumorigenesis such as the cellular proliferation, differentiation, metabolism as well as apoptosis \[[@R2], [@R3]\]. It is available to isolate the microRNAs from the clinical specimens including the plasma, serum, sputum and tissue. Meanwhile, it has a high stability. Due to these advantages, the microRNAs are increasingly becoming an ideal tool for the detection of human cancer.

Aberrant expression of miR-486 (miR-486-5p) has been reported to be associated with different types of human cancer such as hepatocellular carcinoma (HCC) \[[@R4], [@R5]\], lung cancer \[[@R6]\], breast cancer \[[@R7]\], esophageal squamous cell carcinoma (ESCC) \[[@R8]\] and pancreatic cancer (PC) \[[@R9], [@R10]\]. It can act as both the tumor suppressor and oncogene to participant in the development and progression of tumors. The down-regulation of miR-486 can promote the progression of lung cancer \[[@R6]\], HCC \[[@R4], [@R5]\], breast cancer \[[@R7]\] and osteosarcoma \[[@R11]\], while it is usually up-regulated in PC \[[@R9], [@R10]\], chronic myeloid leukemia \[[@R12]\] and gliomas \[[@R13]\]. Recently, a series of articles have identified that miR-486 might be applied as a biomarker for cancer detection and prognosis. However, as a result of the small sample sizes, different microRNA profiling and the differences of the specimen and ethnicity, many articles showed conflicting conclusions and no meta-analysis was conducted to explore the association between miR-486 and diagnosis as well as the prognosis of human cancer. Therefore, this meta-analysis was performed to assess the performance of miR-486 in the detection and prognosis for human cancer.

RESULTS {#s2}
=======

Literature search and the studies' characteristics {#s2_1}
--------------------------------------------------

As described in Figure [1A](#F1){ref-type="fig"}, based on the primary literature research, 402 eligible articles were included, of which 368 articles were removed as duplicate and unrelated articles. And then 7 reviews and 3 articles about miR-486-3p were also excluded, leaving 24 articles with full texts. After carefully reading, another 3 articles were then removed: 1 article without complete data and 2 articles with the same population with other articles. Ultimately, 21 articles \[[@R14]--[@R33]\] with 29 studies were published from 2010 to 2017. 15 articles \[[@R14]--[@R28]\] with 22 studies were about the value of miR-486 for cancer detection while the remaining 6 articles \[[@R29]--[@R33]\] with 7 studies were about the cancer prognosis.

![Flow chart of this meta-analysis of miR-486 in cancer detection (**A**) and the quality of these included articles according to the QUADAS-2 guidelines: proportion of articles with risk of bias (left) and proportion of articles with regarding applicability (right) (**B**).](oncotarget-09-13948-g001){#F1}

Diagnostic meta-analysis {#s2_2}
------------------------

### Studies' characteristics and quality assessment {#s2_2_1}

A total of 15 articles with 22 studies involving in 1315 cases and 1013 controls were analyzed. The main characteristics of the 22 studies were shown in Table [1](#T1){ref-type="table"}. Types of cancer included lung cancer, non-small cell lung cancer (NSCLC), gastric cancer (GC), renal cell cancer (RCC) and pancreatic cancer (PC).The quantitative real-time polymerase chain reaction (qRT-PCR) was used in these studies to test the expression level of miR-486, and the most common reference miRNAs used as the endogenous controls for normalization were RNU6B (U6), miR-39 and miR-16. The quality of the included studies turned out to be generally good and was summarized in Figure [1B](#F1){ref-type="fig"}.

###### The main features of 22 included studies in diagnostic meta-analysis

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study ID         ethnicity            specimen          cas\        con\        Cancer-type   Control-type   stage   miRNA                                                            Reference miRNA         method    SEN (%)   SPE (%)
                                                          e           trol                                                                                                                                                          
  ---------------- -------------------- ----------------- ------ ---- ------ ---- ------------- -------------- ------- ---------------------------------------------------------------- ----------------------- --------- --------- ---------
  Sromek M 2017    Caucasian            Plasma            61     63   50     57   NSCLC         HC             I-IV    miR-16, miR-205,miR-486                                          miR-24-3p               qRT-PCR   80.00     95.00

  Wang X 2016      Asian                plasma            59     56   59     58   NSCLC         BD             I-III   miR-486,miR-210,CYFRA21-1                                        miR-16                  qRT-PCR   84.70     72.80

  Butz H 2016      Caucasian            Urinary Exosome   28     59   18     NA   RCC           HC             NA      miR-126-3p, miR-486-5p                                           miR-16-5p,miR-106a-5p   qRT-PCR   72.40     60.00

  Butz H 2016      Caucasian            Urinary Exosome   81     NA   33     NA   RCC           HC             NA      miR-126-3p, miR-486-5p                                           miR-16-5p,miR-106a-5p   qRT-PCR   81.30     62.50

  Cao Z 2016       Asian                plasma            29     NA   16     NA   PC            BD             I-IV    miR-486-5p,miR-126-3p,miR-106b-3p,miR-938,miR-26b-3p, miR-1285   U6                      qRT-PCR   83.90     80.80

  Cao Z 2016       Asian                plasma            156    NA   57     NA   PC            BD             I-IV    miR-486-5p,miR-126-3p,miR-106b-3p                                U6                      qRT-PCR   82.70     84.40

  Xu JW 2016       Asian                plasma            156    NA   65     NA   PC            HC             I-IV    miR-486-5p                                                       U6                      qRT-PCR   75.00     87.70

  Wang LL 2016     Asian                serum             100    59   50     58   GC            HC             I-IV    miR-486                                                          U6                      qRT-PCR   76.00     98.00

  Yang Y 2016      Asian                plasma            35     NA   30     NA   lung cancer   HC             I-IV    miR-486                                                          cel-miR-39              qRT-PCR   90.00     68.60

  Tai M 2016       Asian                blood             110    65   52     66   LAD           HC             I-IV    20miRs1                                                          miR-159a,U6             qRT-PCR   89.10     100.00

  Tai M 2016       Asian                blood             143    66   49     66   LAD           HC             I-IV    20miRs1                                                          miR-159a,U6             qRT-PCR   94.40     98.00

  Li WS 2016       Asian                plasma            11     59   11     55   NSCLC         HC             I-III   MiR-486                                                          miR-39 ,RNU44           qRT-PCR   90.90     81.80

  Jiang X 2015     Asian                plasma            35     NA   30     NA   lung cancer   BD/HC          I-IV    miR-486                                                          cel-miR-39              qRT-PCR   88.50     83.30

  Zhu C 2014       Asian                plasma            48     57   102    54   GC            HC             I       miR-16,miR-25,miR-92a,miR-451, miR-486-5p                        cel-miR-39              qRT-PCR   72.90     89.20

  Zhu C 2014       Asian                plasma            40     54   40     54   GC            HC             I       miR-16,miR-25,miR-92a,miR-451,miR-486-5p                         cel-miR-39              qRT-PCR   97.50     87.50

  Mozzoni P 2013   Caucasian            plasma            54     69   46     64   NSCLC         BD             I-III   miR-21,miR-486                                                   miR-16                  qRT-PCR   87.00     86.50

  Shen J 2011      Caucasian, African   plasma            58     68   29     66   NSCLC         HC             I-IV    miR-21,miR-126,miR-210,miR-486-5p                                miR-16                  qRT-PCR   86.20     96.60

  Bianchi F 2011   Caucasian            serum             25     NA   39     NA   LAD           HC             I-IV    34miRs2                                                          6miRs3                  qRT-PCR   69.00     84.00

  Bianchi F 2011   Caucasian            serum             34     NA   30     NA   NSCLC         HC             I-IV    34miRs2                                                          6miRs3                  qRT-PCR   71.00     90.00

  Shen Jun 2011    Caucasian, African   plasma            32     66   33     65   NSCLC         BD             I-IV    miR-21,miR-210,miR-486-5p                                        miR-16                  qRT-PCR   75.00     84.90

  Shen J 2011      Caucasian, African   plasma            76     68   80     65   NSCLC         BD             I-IV    miR-21,miR-210,miR-486-5p                                        miR-16                  qRT-PCR   76.30     85.00

  Yu L 2010        Caucasian, African   sputum            36     68   36     67   LAD           HC             I       miR-486,miR-21,miR-200b,miR-375                                  U6                      qRT-PCR   80.60     91.70

  Yu L 2010        Caucasian, African   sputum            64     67   58     65   NSCLC         HC             I-IV    miR-486,miR-21,miR-200b,miR-375                                  U6                      qRT-PCR   70.30     80.00
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

1:miR-451,miR-1290,miR-636,miR-30c,miR-22-3p,miR-19b,miR-486-5p,miR-20b,miR-93,miR-34b,miR-185,miR-126-5p,miR-93-3p,miR-1274a,miR-142-5p,miR-628-5p,miR-486-3p,miR-425,miR-645,miR-24. 2: let-7a, let-7b, let-7d, miR-103, miR-126, miR-133b, miR-139, miR-140, miR-142, miR-142, miR-148a, miR-148b, miR-17, miR-191, miR-22, miR-223, miR-26a, miR-26b, miR-28, miR-29a, miR-30b, miR-30c, miR-32, miR-328, miR-331, miR-342, miR-374, miR-376a, miR-432, miR-484, miR-486, miR-566, miR-92a and miR-98. 3: miR-197, miR-19b, miR-24, miR-146, miR-15b, miR-19a. Abbreviation: N, number of samples; HC, healthy control; BD, benign disease; SEN, sensitivity; SPE, specificity. NSCLC, non-small cell lung cancer; RCC, renal cell cancer; PC, pancreatic cancer; GC, gastric cancer; LAD, lung adenocarcinoma.

Pooled diagnostic performance {#s2_3}
-----------------------------

The significant heterogeneity was observed since I^2^ for SEN and SPE were 62.12% (95% CI: 44.65--79.58%) and 69.43% (95% CI: 56.08--82.78%) respectively. Therefore, we used a random-effect model for this analysis. Results showed that overall pooled SEN and SPE for these 22 studies were 82% (95% CI: 78-85%) and 88% (95% CI: 83--92%) respectively to distinguish patients with cancer from the controls (Figure [2](#F2){ref-type="fig"}). The positive likelihood ratio (PLR) and negative likelihood ratio (NLR) were 6.9 (95% CI: 4.8--9.7) and 0.21 (95% CI: 0.17--0.26) respectively, and the diagnostic odds ratio (DOR) was 33 (95% CI: 20--55). The summary receiver operating characteristic (SROC) curve was performed and the AUC was 0.91 (95% CI: 0.88--0.93) (Figure [3A](#F3){ref-type="fig"}).

![Forest plots of sensitivity and specificity for the cancer diagnosis of miR-486\
Both the sensitivity and specificity of each study were showed by square with its 95% Confidence interval showed by the error bars.](oncotarget-09-13948-g002){#F2}

![SROC curve of the miR-486 as diagnostic tools for cancer (**A**) and the Deek's test for assessing the publication bias for miR-486 in the detection of cancer (**B**).](oncotarget-09-13948-g003){#F3}

Publication bias and sensitivity analysis {#s2_4}
-----------------------------------------

In this meta-analysis, Deek's funnel plot asymmetry test was applied to test the probability of publication bias. The funnel plot was symmetry (Figure [3B](#F3){ref-type="fig"}) and *P* value equaled 0.39, which demonstrated the publication bias didn't exist in these studies. Sensitivity analysis was also conducted but failed to find the sources of heterogeneity.

Subgroup analysis and meta-regression analysis {#s2_5}
----------------------------------------------

A multivariate-meta-regression was performed to detect the potential causes of the heterogeneity in both SEN and SPE. The following factors were included: miRs (miR-486 alone or miR-486 with other miRNAs); specimen (circulating or not circulating); ethnicity (Asian, Caucasian or Caucasian/African); control-type (benign disease or healthy controls); stage (early stage or overall stage); cancer-type (lung cancer, gastric cancer, pancreatic cancer and renal cell carcinoma and sample-size (\>=100 or \< 100). The results demonstrated that specimen (*P* \< 0.05) might explain the heterogeneity in SPE shown in Figure [4](#F4){ref-type="fig"}. Meanwhile, the subgroup analyses were also conducted and the results were presented in Table [2](#T2){ref-type="table"}. Subgroup analysis by specimen showed that studies with circulating samples exhibited higher diagnostic accuracy with SEN: 81% (95% CI: 78--84%), SPE: 86% (95% CI: 83-89%) and AUC: 0.90 (95% CI: 0.87-0.92) (Figure [5A](#F5){ref-type="fig"}) than studies with not circulating samples with the SEN: 76% (95% CI: 70--82%), SPE: 76% (95% CI: 62--86%) and AUC: 0.78 (95% CI: 0.75--0.82) (Figure [5B](#F5){ref-type="fig"}) respectively. In the subgroup of the ethnicity, the miR-486 obtained a better diagnostic value in the Asian population with the SEN: 86% (95% CI: 80--90%), SPE: 90% (95% CI: 84--94%) and AUC: 0.94 (95% CI: 0.91--0.95) (Figure [6A](#F6){ref-type="fig"}) when Compared with the Caucasian population with the SEN: 79% (95% CI: 74--83%), SPE: 83% (95% CI: 71--91%) and AUC: 0.80 (95% CI: 0.76--0.83) (Figure [6B](#F6){ref-type="fig"}) and the Caucasian/African population with SEN: 78% (95% CI: 71--84%), SPE: 87% (95% CI: 80--92%) and AUC: 0.89 (95% CI: 0.86--0.91) (Figure [6C](#F6){ref-type="fig"}) respectively. With respect to the other types of subgroup analysis, there were no significant differences in the diagnostic accuracy of miR-486 and since there were only 3 studies for early stage and 2 studies that we did not obtain the information about the stage, we only conducted the subgroup analysis for the overall stage of human cancer. However, for the subgroup analysis of NSCLC, it obtained a pretty high diagnostic value with the sensitivity, specificity were 82% (95% CI: 77--87%), 90% (95% CI: 84--94%) respectively as well as the AUC was 0.92 (95% CI: 0.89--0.94) (Figure [6D](#F6){ref-type="fig"}).

![Forest plots for the Meta-regression analysis: sensitivity and specificity\
The factors included ethnicity, specimen, control, stage, cancer, miRs and sample size.](oncotarget-09-13948-g004){#F4}

###### The subgroup analysis for the selected studies

  Subgroups           No.of studies   SEN \[95% CI\]        SPE \[95% CI\]        PLR \[95% CI\]      NLR \[95% CI\])       DOR \[95% CI\])   AUC \[95% CI\]
  ------------------- --------------- --------------------- --------------------- ------------------- --------------------- ----------------- ---------------------
  MiRNA profiling                                                                                                                             
   single             4               0.78 \[0.72--0.83\]   0.90 \[0.80--0.95\]   7.6 \[3.9--14.6\]   0.24 \[0.19--0.32\]   31 \[15--64\]     0.84 \[0.81--0.87\]
   multiple           18              0.83 \[0.79--0.86\]   0.90 \[0.86--0.93\]   8.0 \[5.7--11.4\]   0.19 \[0.15--0.24\]   42 \[25--70\]     0.93 \[0.90--0.95\]
  Specimen                                                                                                                                    
   circulating        18              0.81 \[0.78--0.84\]   0.86 \[0.83--0.89\]   6.0 \[4.7--7.6\]    0.22 \[0.18--0.26\]   28 \[20--37\]     0.90 \[0.87--0.92\]
   not circulating    4               0.76 \[0.70--0.82\]   0.76 \[0.62--0.86\]   3.2 \[1.9--5.4\]    0.31 \[0.23--0.41\]   10 \[5--21\]      0.78 \[0.75--0.82\]
  Ethnicity                                                                                                                                   
   Asian              11              0.86 \[0.80--0.90\]   0.90 \[0.84--0.94\]   8.9 \[5.1--15.4\]   0.16 \[0.11--0.23\]   55 \[25--120\]    0.94 \[0.91--0.95\]
   Caucasian          6               0.79 \[0.74--0.83\]   0.83 \[0.71--0.91\]   4.7 \[2.6--8.3\]    0.25 \[0.20--0.33\]   18 \[9--39\]      0.80 \[0.76--0.83\]
  Caucasian/African   5               0.78 \[0.71--0.84\]   0.87 \[0.80--0.92\]   6.2 \[3.7--10.4\]   0.25 \[0.18--0.35\]   24 \[11--53\]     0.89 \[0.86--0.91\]
  Control--type                                                                                                                               
   HC                 15              0.81 \[0.76--0.86\]   0.91 \[0.84--0.95\]   8.7 \[5.0--15.1\]   0.21 \[0.15--0.28\]   42 \[19--92\]     0.91 \[0.88--0.93\]
   BD                 6               0.82 \[0.78--0.85\]   0.83 \[0.77--0.87\]   4.7 \[3.6--6.1\]    0.22 \[0.18--0.27\]   21 \[14--32\]     0.87 \[0.84--0.90\]
  Cancer type                                                                                                                                 
   NSCLC              13              0.82 \[0.77--0.87\]   0.90 \[0.84--0.94\]   8.4 \[5.0--14.1\]   0.20 \[0.15--0.26\]   43 \[20--92\]     0.92 \[0.89--0.94\]
  Sample size                                                                                                                                 
   \> = 100           12              0.82 \[0.77--0.86\]   0.90 \[0.82--0.94\]   8.1 \[4.4--14.7\]   0.20 \[0.15--0.27\]   40 \[18--90\]     0.90 \[0.87--0.92\]
   \< 100             10              0.82 \[0.75--0.87\]   0.86 \[0.81--0.90\]   5.8 \[4.1--8.2\]    0.21 \[0.15--0.30\]   28 \[15--51\]     0.91 \[0.88--0.93\]
  Stage                                                                                                                                       
   overall stage      17              0.82 \[0.78--0.85\]   0.89 \[0.85--0.93\]   7.8 \[5.2--11.6\]   0.20 \[0.16--0.26\]   38 \[21--68\]     0.91 \[0.88--0.93\]
   Overall studies    22              0.82 \[0.78--0.85\]   0.88 \[0.83--0.92\]   6.9 \[4.8--9.7\]    0.21 \[0.17--0.26\]   33 \[20--55\]     0.91 \[0.88--0.93\]

No: the number of the studies; HC, healthy control; BD, benign pulmonary disease; SEN, sensitivity; SPE, specificity; PLR, positive likelihood ratio; NLR, negative likelihood ratio; DOR, Diagnostic Odds Ratio; AUC, area under the curve.

![SROC curve of the miR-486 from circulating samples (**A**) and the other specimen (**B**).](oncotarget-09-13948-g005){#F5}

![SROC curve of the miR-486 in detection of Asian population (**A**), Caucasian population (**B**) and the Caucasian/ African population (**C**) as well as the SROC curve of miR-486 in the diagnosis of non-small cell lung cancer (**D**).](oncotarget-09-13948-g006){#F6}

Prognostic meta-analysis {#s2_6}
------------------------

### Studies' characteristics and quality assessment {#s2_6_1}

A total of 761 participants with cancer from 6 articles on 7 studies were included. The main characteristics of the 7 studies were shown in Table [3](#T3){ref-type="table"} Most studies investigated miR-486 by qRT-PCR. The overall survival (OS), progression-free survival (PFS) and relapse free survival (RFS) were used to evaluate the outcome of the cohorts. Types of the cancer included NSCLC, ESCC, GC and HCC. The results of the studies' quality assessment were also included in Table [3](#T3){ref-type="table"}.

###### The main features of 7 included studies in prognostic meta-analysis

  Study ID           sex (male/ female   age   ethnicity   specimen   cancer-type   stage    miRNA        reference miRNA     method      outcome   follow-up (month)   HR     ll     ul      NOS
  ------------------ ------------------- ----- ----------- ---------- ------------- -------- ------------ ------------------- ----------- --------- ------------------- ------ ------ ------- -----
  Guo J 2016         25/9                57    Asian       serum      NSCLC         III-IV   miR-486      cel-miR-39          qRT-PCR     PFS       \> 8.5              2.04   1.00   4.13    8
  Ren CL 2016        137/36              NA    Asian       tissue     ESCC          I-IV     miR-486-5p   Scramble-miR        miRNA-LNA   OS        93.6                4.32   2.62   7.14    7
  Ren CL 2016        73/21               NA    Asian       tissue     GC            I-IV     miR-486-5p   Scramble-miR        miRNA-LNA   OS        87.6                2.46   1.35   4.50    7
  Li WS 2015         7/4                 59    Asian       plasma     NSCLC         I-III    miR-486      cel-miR-39 ,RNU44   qRT-PCR     RFS       24                  0.11   0.01   1.06    7
  Petriella D 2015   21/9                65    Caucasian   serum      NSCLC         III-IV   miR-486-5p   U6                  qRT-PCR     PFS       \> 15               5.59   1.32   23.26   7
  Wang LM 2015       94/22               54    Asian       serum      HCC           NA       MiR-486-5p   U6                  qRT-PCR     RFS       24                  1.27   1.12   1.43    7
  Hu ZB 2010         222/81              60    Asian       serum      NSCLC         I-III    miR-486      NA                  qRT-PCR     OS        61.8                0.50   0.34   0.74    7

Abbreviation: HR, hazard ratio; ll, lower limit; ul, upper Limit; NOS, Newcastle-Ottawa Scale; NSCLC, non-small cell lung cancer; ESCC, esophageal squamous cell carcinoma; GC, gastric cancer; HCC, hepatocellular carcinoma; OS, overall survival; PFS, progression-free survival; RFS, relapse free survival.

Association between miR-486 and outcomes {#s2_7}
----------------------------------------

A random-effects model was used since the heterogeneity among studies existed (I^2^ = 89.9, *P* = 0.000). The pooled HR (hazard ratio) was 0.48 (95% CI: --0.13--1.08) for low versus high miR-486 expression as shown in Figure [7A](#F7){ref-type="fig"}. Low miR-486 expression did not increase the risk of poor outcome compared with the high miR-486 expression. And the studies were so few that we did not conduct subgroup analysis for the prognostic meta-analysis.

![Forest plots of sensitivity and specificity for miR-486 in cancer prognosis (**A**) and the Begg's funnel plot for the sensitivity analysis (**B**).](oncotarget-09-13948-g007){#F7}

Publication bias and sensitivity analysis {#s2_8}
-----------------------------------------

Publication bias was checked by Begg's funnel plot and Egger's test under the random-effects model (Figure [7B](#F7){ref-type="fig"}). Although the Begg's funnel plot seemed asymmetric, the *P* value of the Egger's regression intercept was 0.676, indicating that there was no obvious publication bias among these studies. The sensitivity analysis was also conducted but failed to find the sources of heterogeneity.

DISCUSSION {#s3}
==========

Cancer biomarkers are critical for cancer detection and predicting the outcome as well as choosing the suitable treatment methods. As involving in various biological processes in cancer, miRNA was considered to play a crucial role in cancer diagnosis and prognosis surveillance.

MiR-486 has been reported to be involved in different types of cancer. Research in the mechanism of miR-486 found that the down-regulation of miR-486 could target genes such as ARHGAP5 to inhibit cell migration and invasion *in vitro* and metastasis *in vivo* in lung cancer \[[@R6]\] and it could inhibit cancer cell proliferation, migration and invasive *in vitro* and suppress HCC growth *in vivo* by targeting PIK3R1 \[[@R4]\]. Furthermore, miR-486 might inhibit cell growth of papillary thyroid carcinoma by targeting fibrillin-1 \[[@R34]\] and estrogen receptor-mediated miR-486 could regulate expression of OLFM4 in ovarian cancer \[[@R35]\].

This present meta-analysis aimed to estimate the pooled effect of miR-486 expression on diagnosis and prognosis of human cancer. The diagnostic accuracy of miR-486 was pretty high. The adjusted pooled SEN, SPE and AUC were 82% (95% CI: 78--85%), 88% (95% CI: 83--92%) and 0.91 (95% CI: 0.88--0.93) respectively. With respect to the subgroup analysis, the circulating miR-486 obtained a higher diagnostic value than miR-486 from other specimen. In addition, the accuracy of miR-486 to detect cancer for Asian population was higher than Caucasian or Caucasian/ African population. The pooled AUC of 0.92 (95% CI: 0.89-0.94) indicated that the performance of miR-486 to detect NSCLC was feasible. As for the value of miR-486 on prognosis of cancer, the pooled HR was 0.48 (95% CI: -0.13--1.08) for low versus high miR-486 expression showed that low miR-486 expression did not increase the risk of poor outcome.

To our best knowledge, this meta-analysis was the first one to explore the effect of miR-486 on cancer diagnosis and prognosis. Although we perform this meta-analysis strictly according to the PRISMA guidelines, there were still some limitations that could not be neglected in this meta-analysis. First, the types of cancer included and the studies of each cancer as well as the samples of cases were so few that we could not conduct the subgroup analysis for the prognostic meta-analysis and these limitations might partly contribute to the negative result. Second, the heterogeneity among these studies could not be neglected and some articles might be missed or not be published online that did not be included in this meta-analysis. Third, most studies were from China in the prognostic meta-analysis and the results might just represent the prognostic value of miR-486 on Chinese cancer. Therefore, Studies on the large samples are still demanded to verify our results.

MATERIALS AND METHODS {#s4}
=====================

Search strategy {#s4_1}
---------------

We based our meta-analysis on the Preferred Reporting Items for meta-analyses (PRISMA). We searched PubMed, Cochrane library, Embase, Chinese National Knowledge Infrastructure (CNKI) and Wanfang databases to find all associated articles in order to investigate the potential utility of miR-486 as a diagnostic and prognostic surveillance tool for human cancer. The combination of the Medical Subject Headings (MeSH) and the keywords: (miR-486 or hsa-miR-486 or microRNA-486 or miR486) and (cancer or tumor or carcinoma or neoplasm) was used (updated to September 13, 2017). We also searched reference lists of the reviews aiming at obtaining other acceptable articles.

Study selection {#s4_2}
---------------

There was a series of criteria for records inclusion as well as exclusion. For inclusion, records needed to meet the following criteria: 1) Patients of the cases were with cancer; 2) The controls were healthy controls (HC) or with benign diseases (BD); 3) Assess the diagnostic or prognostic value of miR-486 (miR-486-5p); 4) The TP, FP, FN, TN for the diagnosis and HR (hazard ratio) and its 95% CI for the prognosis can be extracted or calculated from the articles. For the exclusion, the criteria as follows: 1) Records that were review, meta-analysis and duplicate publications as well as the records unrelated; 2) Records without complete data or with the same population; 3) Records were about the miR-486-3p.

Data collection and quality assessment {#s4_3}
--------------------------------------

The data was collected independently by two authors as follows: the first author, year of publication, subject's demographic characteristics (ethnicity, mean or median age, sample size, testing method of miR-486 and the types of the controls and cancer); types of the specimen; follow-up time and the outcomes; miRNA profiling and the data used for this meta-analysis (SEN, SPE, TP, FP, FN, TN, HR and its 95% CI). All HRs were reformatted as low miR-486 expression versus high miR-486 expression. We assessed the quality of these articles with the Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) guidelines for the diagnostic records and followed the guidelines of the Newcastle-Ottawa Scale (NOS) for the prognostic publications \[[@R36], [@R37]\].

Statistical analysis {#s4_4}
--------------------

We performed the statistical analysis using the STATA 11.0 (STATA-Corp, College Station, TX, version 11.0) software and RevMan 5.3 (version 1.4) software. A bivariate random effect-regression model was applied to assess the pooled SEN \[TP/ (FN+TP)\], SPE \[TN/ (FP+TN)\], the positive likelihood ratio (PLR) \[(SEN/ (1-SEN)\], the negative likelihood ratio (NLR) \[(1-SPE)/SPE)\], the diagnostic odds ratio (DOR) \[PLR/ NLR\] and the pooled HR with its 95% Confidence Interval (95% CI) respectively. We also constructed the SROC curve and calculated the AUC value. Simultaneously, we assessed the heterogeneity among the selected studies through the *Q* test and the I^2^ value \[[@R38]\]. The *P* value for the *Q* test less than 0.05 or the I^2^ ≥ 50% demonstrated that there was heterogeneity among the included studies. For the diagnostic meta-analyses, meta-regression analysis and subgroup analysis (grouped by miRNA profiling: single miR-486 and multiple miRNAs including miR-486 and other miRNAs; specimen: circulating and not circulating; ethnicity: Asian, Caucasian and Caucasian/African; control-type: benign disease and healthy controls; stage: early stage and not only early stage; cancer-type: lung cancer, gastric cancer, pancreatic cancer and renal cell carcinoma and sample size: \>= 100 and \< -100) were used to identify the potential sources of the heterogeneity and the Deek 's funnel plot asymmetry test was also applied to explore the publication bias, with the *P* value less than 0.01 considered significant \[[@R39]\]. As for the prognostic meta-analyses, Begg's and Egger's tests were selected to evaluate the included studies for the possibility of publication bias. Finally, the sensitivity analysis was conducted to explore the possible sources of heterogeneity for both the diagnosis and the prognosis meta-analysis.

CONCLUSIONS {#s5}
===========

This was the first meta-analysis to confirm the potential value of miR-486 on cancer diagnosis and prognosis. The expression of miR-486 might be an effective biomarker for detection of human cancer.

Thanks for the efforts of all the authors.
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miR-486

:   has-miR-486/ has-miR-486-5p

miRNA

:   microRNA

mRNA

:   messenger RNA

3'-UTR

:   3'-untranslated region

NSCLC

:   non-small cell lung cancer

HCC

:   hepatocellular carcinoma

ESCC

:   esophageal squamous cell carcinoma

PC

:   pancreatic cancer

GC

:   gastric cancer

RCC

:   renal cell cancer

PRISMA

:   preferred Reporting Items for meta-analysis

HC

:   Healthy Control

BD

:   benign disease

SEN

:   sensitivity

SPE

:   specificity

SROC

:   summary receiver operating characteristic

AUC

:   the area under the SROC curve

CNKI

:   Chinese national knowledge infrastructure

PLR

:   positive likelihood ratio

NLR

:   negative likelihood ratio

DOR

:   diagnostic odds ratio

TP

:   true positive

FP

:   false positive

FN

:   false negative

TN

:   true negative

qRT-PCR

:   quantitative real-time polymerase chain reaction

HR

:   hazard ratio

OS

:   overall survival

PFS

:   progression-free survival

RFS

:   relapse free survival

QUADAS-2

:   the Quality Assessment of Diagnostic Accuracy Studies-2

NOS

:   the Newcastle-Ottawa Scale
